

HEALTHCARE MONTHLY

MARCH 2021

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSIS
			<ul style="list-style-type: none"> Jazz Pharmaceuticals (NasdaqGS:JAZZ) entered into an agreement to acquire GW Pharmaceuticals (NasdaqGS:GWPH) GW focuses on developing and commercializing novel therapeutics from its proprietary cannabinoid product platform Jazz develops and commercializes neuroscience and oncology pharmaceutical products Total consideration: \$6.9 billion in cash and equity (50% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 12.2x
BioTech/Pharma			<ul style="list-style-type: none"> Horizon Therapeutics entered into a definitive agreement to acquire Viela Bio (NasdaqGS:VIE) Viela researches and develops treatments for severe inflammation and autoimmune diseases Horizon develops prescription drugs for mild to moderate pain relief and arthritis Total consideration: \$2.9 billion in cash (53% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 229.7x
			<ul style="list-style-type: none"> Merck & Co. (NYSE:MRK) entered into a definitive agreement to acquire Pandion Therapeutics (NasdaqGS:PAND) Pandion develops various therapeutics focused on autoimmune diseases Merck manufactures and distributes prescription and oncology products, vaccines and biologic therapies Total consideration: \$1.8 billion in cash (134% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 209.2x
Life Sci / Diagnostics			<ul style="list-style-type: none"> ICON (NasdaqGS:ICLR) entered into an agreement to acquire PRA Health Sciences (NasdaqGS:PRAH) PRA provides outsourced clinical development and data solution services ICON specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process Total consideration: \$10.8 billion in cash and equity (30% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 3.8x

HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index



SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Cognate BioServices	Charles River Laboratories (NYSE:CRL)	Cognate provides gene therapy products and development and manufacturing services to biotechnology companies and institutions Total consideration: \$875 million in cash

Allergan Biologics	Pharmaron Beijing	Allergan Biologics, based in the United Kingdom, provides consultancy, biopharmaceutical process development and analytical development services Total consideration: \$451 million in cash
--------------------	-------------------	--

Guide Therapeutics	Beam Therapeutics (NasdaqGS:BEAM)	Guide Therapeutics discovers and develops nanoparticles to deliver therapeutics for gene therapy Total consideration: \$440 million in cash and milestones
--------------------	-----------------------------------	---

Target	Acquiror	Life Sci / Diagnostics Transactions
Decipher Biosciences	Veracyte (NasdaqGM:VCYT)	Decipher develops and sells genomic testing products with a primary focus on prostate cancer Total consideration: \$600 million in cash and equity

Mesa Biotech	Thermo Fisher Scientific (NYSE:TMO)	Mesa develops, manufactures and sells molecular diagnostic tests focused on respiratory syncytial viruses Total consideration: \$450 million in cash Implied Enterprise Value / LTM Total Revenue Multiple: 12.2x
--------------	-------------------------------------	---

Ginolis	Cellink	Ginolis provides automation and high precision liquid handling solutions for diagnostic and medtech industries Total consideration: \$74 million in cash and equity Implied Enterprise Value / LTM Total Revenue Multiple: 3.4x
---------	---------	---

Target	Acquiror	Health Services Transactions
Tsukui Holdings Corporation	MBKP Life	Tsukui, based in Japan, provides home and nursing care services across Home Care, Pay Nursing Home, Assisted-Living Facilities and Human Resource Development Total consideration: \$451 million in cash Implied Enterprise Value / LTM Total Revenue Multiple: 0.8x

CRH Medical Corporation (TSX:CRH)	WELL Health Technologies (TSX:WELL)	CRH, based in Canada, provides anesthesia services for patients undergoing endoscopic procedures Total consideration: \$300 million in cash (83% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 4.3x
-----------------------------------	-------------------------------------	---

rfxcel Corporation	Antares Vision, Inc.	rfxcel Corporation provides SaaS-based track and trace solutions for the pharmaceutical supply chain Total consideration: \$120 million in cash and milestones Implied Enterprise Value / LTM Total Revenue Multiple: 8.8x
--------------------	----------------------	--

Target	Acquiror	Medical Device Transactions
Medi-Tate	Olympus Corporation	Medi-Tate, based in Israel, manufactures and sells medical devices for benign prostatic hyperplasia treatment Total consideration: \$211 million in cash and milestones

Contura	Axonics Modulation Technologies	Contura, based in the United Kingdom, manufactures Bulkamid, a soft hydrogel bulking agent for women with stress urinary incontinence Total consideration: \$199 million in cash and milestones
---------	---------------------------------	--

Simplify Medical	NuVasive (NasdaqGS:NUVA)	Simplify Medical develops, manufactures and sells cervical and lumbar artificial discs for the spine Total consideration: \$150 million in cash and milestones
------------------	--------------------------	---

Selected TM Capital Healthcare Experience

\$65 MILLION
SERIES C EQUITY CAPITAL




HAS RECEIVED A GROWTH EQUITY INVESTMENT FROM




HAS SOLD ITS MEDICAL BUSINESS TO



A PORTFOLIO COMPANY OF



TM Capital's Healthcare Industry Contacts



James McLaren
Managing Director
jmclaren@tmcapital.com
212.809.1414



Michael Goldman
Managing Director
mgoldman@tmcapital.com
212.809.1419



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



John Dean
Principal
jdeen@tmcapital.com
404.996.6234



Steve Hunter
Managing Director, Sponsor Coverage
mgoldman@tmcapital.com
404.996.6232